[Psoriatic erythroderma treated with etanercept].

نویسندگان

  • E Piqué-Duran
  • J A Pérez-Cejudo
چکیده

Sección de Dermatología, Hospital General de Lanzarote, Spain radiological data to support this hypothesis. Furthermore, the patient was not treated with antituberculous drugs and the cutaneous lesions healed with topical corticosteroid therapy alone. In conclusion, we describe the case of a patient who presented an episode consistent with generalized pustular psoriasis after a tuberculin test, a possible trigger not previously reported in the literature.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

[Evaluation of dermatological services implemented in the primary care setting].

large series have been published and no treatment protocol has been established. Systemic therapies such as retinoids, methotrexate, and cyclosporine, among others, either alone or in combination, have traditionally achieved mixed results.5 However, the market introduction of biological therapies provided new options for the treatment of this variant of psoriasis. Experience with biological the...

متن کامل

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.

BACKGROUND Etanercept, a tumour-necrosis-factor inhibitor, has shown efficacy in the treatment of rheumatoid arthritis. Psoriatic arthritis and psoriasis are disease states in which tumour necrosis factor, a proinflammatory cytokine, is present in increased concentrations in joints and in the skin. Therefore, psoriatic arthritis and psoriasis may be appropriate therapeutic targets for etanercep...

متن کامل

Erythrodermic Psoriasis Treated with Apremilast

Erythroderma is a rare potentially deadly exfoliative dermatitis characterized by diffuse cutaneous erythema which may be associated with multi-organ dysfunction. Therefore, it is imperative to recognize and treat it promptly. Erythrodermic psoriasis is the most common form of erythroderma. Management of this condition is largely based on aggressive supportive care and the use of anti-inflammat...

متن کامل

Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.

OBJECTIVE To evaluate the effects of etanercept treatment on patient-reported outcomes (PRO) in patients with psoriatic arthritis (PsA). METHODS A 24-week double-blind comparison to placebo was followed by a 48-week open-label phase in which all eligible patients received etanercept. PRO were measured using the Stanford Health Assessment Questionnaire Disability Index (HAQ-DI), the Medical Ou...

متن کامل

J Turk Acad Dermatol 2015; 9 (3): 1593r1

Background: Tumor necrosis factor-alpha (TNF-α) is a proinflammatory cytokine that plays an immunomodulatory role in a variety of systemic and dermatologic disease. Its blockade can be achieved by using specific inhibitors like etanercept. At present, etanercept is approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis and psoriasis treatme...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Actas dermo-sifiliograficas

دوره 98 7  شماره 

صفحات  -

تاریخ انتشار 2007